Supplementary Figures 1-7 and Table S1 from Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in <i>PIK3CA</i>-Mutant Colorectal Cancer

Supplementary Table S1: Mutational status of common oncogenes in CRC and STAD cell lines. Supplementary Figure S1: Mutant PIK3CA does not regulate LSD1 expression. Supplementary Figure S2: DNase signal is not generally depleted at TSS's, and LSD1 does not reduce global H3K4me2. Supplementary Figure S3: RCOR1 is generally not upregulated in PIK3CA mutant versus WT in cancers arising from non-gastrointestinal tissues, and generally does not correlate with LSD1 expression. Supplementary Figure S4: LSD1 KO reduces cell viability over time in HT29 but not SW480 cells. Supplementary Figure S5: Inhibiting AKT does not reduce Snail protein level in PIK3CA WT or kinase domain mutant cells, and the LSD1-AKT-GSK3b-Snail axis is context dependent. Supplementary Figure S6: LSD1 is upregulated in PIK3CA mutants classified as CRC subtype CMS4, where C2 domain mutations are also most common. Supplementary Figure S7: EGF treatment causes morphological changes in HT29 WT but not LSD1 KO cells.</p

Supplementary Materials and Methods from Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in <i>PIK3CA</i>-Mutant Colorectal Cancer

Contains additional details on bioinformatic analyses, including references for packages used.</p

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Response

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Response

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Response

Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Response

Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Response

Supplementary Table S2 from Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML

Frequency of recurrent mutations in the AML cohort</p

Supplementary Figures S1-S6 from Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML

Supplementary Figures S1-S6</p

Supplementary Table S3 from Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML

Drug response of sequenced patient-derived cases</p